What to Test for in Patients With Early- or Late-Stage Breast Cancer
Opening their program on HR+/HER2- metastatic breast cancer, expert oncologists consider the growing list of therapeutic targets to test for in patients with early or late-stage disease.
EP: 1.What to Test for in Patients With Early- or Late-Stage Breast Cancer
EP: 2.Novel Testing Methodologies in Breast Cancer Management
EP: 3.What is the Role of Germline Testing in Patients With Breast Cancer?
EP: 4.Patient Case 1: Mutated ESR1 in HR+/HER2- Metastatic Breast Cancer
EP: 5.Optimal ESR1 Testing Strategies in HR+/HER2- Metastatic Breast Cancer
EP: 6.HR+/HER2- Metastatic Breast Cancer: Impact of ESR1 Mutation on Treatment
EP: 7.Trial Data: 2L Therapy After ET + CDK4/6i in HR+/HER2- Metastatic Breast Cancer
EP: 8.Considerations for Selecting and Sequencing Therapy in HR+/HER2- mBC
EP: 9.EMERALD: Elacestrant in Relapsed/Refractory HR+/HER2- mBC
EP: 10.Relapsed/Refractory HR+/HER2- mBC: Real-World Applications of the EMERALD Trial
EP: 11.Patient Case 2: Unmutated HR+/HER2- Metastatic Breast Cancer
EP: 12.TROPiCS-02: Sacituzumab Govitecan in Relapsed/Refractory HR+/HER2- mBC
EP: 13.DESTINY-Breast04: T-DXd in HER2-Low Metastatic Breast Cancer
EP: 14.Evolving Role of Antibody Drug Conjugates in Metastatic Breast Cancer
EP: 15.HR+/HER2- Metastatic Breast Cancer: Future Directions in Care
Transcript:
Joyce O'Shaughnessy, MD: Thank you for joining us for this Targeted Oncology™ Virtual Tumor Board®. In today’s presentation, my colleagues and I will review 2 clinical cases of hormone receptor-positive breast cancer and discuss commonly observed targetable genomic alterations and outline our approaches to biomarker testing and share our perspectives on key clinical trial data that may impact our decisions and recommendations for these patients. I’m Joyce O’Shaughnessy, a breast medical oncologist at Baylor University Medical Center, Texas Oncology, and US Oncology in Dallas, Texas. And I'm very pleased to be joined here today by 2 great clinicians and scientists who work together very commonly on molecular tumor boards, I'm very excited to hear. And I'm going to let them introduce themselves. So maybe Komal.
Komal Jhaveri, MD, FACP: Thank you so much. It's such a pleasure to be here today joining for this virtual tumor board. Very excited for that so thank you for having me. I'm Komal Jhaveri, I'm a breast medical oncologist at Memorial Sloan Kettering Cancer Center in New York. I serve as a section head for our endocrine therapy research program, and I also serve as a clinical director for the early drug development service at Memorial Sloan Kettering, so thank you.
Joyce O'Shaughnessy, MD: And Pedram?
Pedram Razavi, MD, PhD: Hi, everyone. Pedram Razavi. Delighted to be here. I'm also a breast medical oncologist at Memorial Sloan Kettering. I lead the breast molecular tumor board here and also the breast translational program, and also, I lead the liquid biopsy and genomics as part of MSK biomarker development program.
Joyce O'Shaughnessy, MD: Awesome. Fantastic. This is a great group here. We have a very interesting discussion, no question. We're going to start with the topic of molecular testing methodology, what should be our approach for early-stage and for late-stage breast cancer. So, this slide shows us some of the common molecular targets we look at in early-stage breast cancer with germline testing, hormone receptor status HER2, Ki-67 and sometimes genomic signatures that are prognostic and sometimes predictive for chemotherapy benefit. And then in metastatic breast cancer, we have a larger number of potential targets, and this is growing larger every year it seems, with our usual hormone receptor status HER2, but of course, PD-L1 expression, germline, but also some somatic mutations that are helpful, like BRCA1/2 and PALB2, and then estrogen receptor mutations, ESR1 mutations, and then mutations that lead to activation of the PI3 kinase pathway such as PIK3CA, AKT, or loss of PTEN. And then rare but very important mutations are fusions such as RET, NTRK, or high tumor mutation burden, or microsatellite instability. And this is, I'm sure, not an exhaustive list, and Pedram and Komal do a lot of phase 1 work and a lot of matching of patients with molecular alterations to therapeutic options. I'm sure their list is a lot longer than this. But this is probably from our day-to-day practice, a lot of what we focus on.
Transcript is AI-generated and edited for clarity and readability.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More
